MX2012010560A - Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. - Google Patents

Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo.

Info

Publication number
MX2012010560A
MX2012010560A MX2012010560A MX2012010560A MX2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A MX 2012010560 A MX2012010560 A MX 2012010560A
Authority
MX
Mexico
Prior art keywords
fusion protein
dlk1
cancer metastasis
active ingredient
composition
Prior art date
Application number
MX2012010560A
Other languages
English (en)
Other versions
MX342222B (es
Inventor
Young Woo Park
Kiwon Jo
Donghee Lee
Jung Yu
Ji Hyun Park
Chan-Woong Park
Eun Jin Kim
Yun Jung Park
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Publication of MX2012010560A publication Critical patent/MX2012010560A/es
Publication of MX342222B publication Critical patent/MX342222B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención involucra la construcción de un vector de expresión recombinante que involucra la combinación de un gen dominio Fc del anticuerpo IgG de la región extracelular de DLK1, y la expresión y purificación de la proteína de fusión DLK1-Fc en células 293E, y se ha confirmado que la proteína de fusión DLK1-Fc reduce notablemente la migración de la célula cancerígena y que es eficaz como un fármaco para un concepto para la supresión práctica de la metástasis del cáncer a través del cálculo del parámetro farmacocinético. La presente invención puede utilizarse ventajosamente como un ingrediente activo en una composición para inhibir la metástasis del cáncer ya que la proteína de fusión DLK1-Fc es más estable que la proteína no de fusión, reduce notablemente la migración del cáncer en varias cepas de células cancerígenas y tiene un efecto inhibidor de la metástasis impresionante aún a una baja concentración.
MX2012010560A 2010-03-16 2010-04-13 Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo. MX342222B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100023180A KR100982170B1 (ko) 2010-03-16 2010-03-16 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물
PCT/KR2010/002277 WO2011115323A1 (ko) 2010-03-16 2010-04-13 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Publications (2)

Publication Number Publication Date
MX2012010560A true MX2012010560A (es) 2012-12-10
MX342222B MX342222B (es) 2016-09-21

Family

ID=43010111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010560A MX342222B (es) 2010-03-16 2010-04-13 Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo.

Country Status (11)

Country Link
US (1) US8785392B2 (es)
EP (1) EP2548887B1 (es)
JP (1) JP5367905B2 (es)
KR (1) KR100982170B1 (es)
CN (1) CN102341408B (es)
AU (1) AU2010348423B2 (es)
BR (1) BR112012023416A2 (es)
CA (1) CA2792413C (es)
MX (1) MX342222B (es)
RU (1) RU2531756C2 (es)
WO (1) WO2011115323A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100982170B1 (ko) 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제
KR101461706B1 (ko) 2011-04-04 2014-11-18 한국생명공학연구원 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
KR101995751B1 (ko) * 2012-01-05 2019-07-03 주식회사 와이바이오로직스 Ｄｌｋ１ 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제
WO2014129590A1 (ja) * 2013-02-21 2014-08-28 国立大学法人九州大学 Ｃｙｃｌｉｎ Ｄ１遺伝子発現抑制剤および抗腫瘍剤
CN105765063B (zh) 2013-09-30 2021-05-07 中外制药株式会社 应用改变的辅助噬菌体制备抗原结合分子的方法
CN104711341B (zh) * 2013-12-17 2019-10-22 上海市肿瘤研究所 Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用
WO2019050362A2 (ko) * 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
CN108130311B (zh) * 2017-12-19 2020-12-08 柴怡 一种人原代结肠癌肝转移细胞株hcs1220

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ES2151542T3 (es) * 1992-12-11 2001-01-01 Us Health Gen del tipo delta expresado en tumores neuroendocrinos.
EP0938332A4 (en) * 1996-03-01 2003-05-28 Imclone Systems Inc USE OF DELTA-LIKE PROTEINS TO INHIBIT THE DIFFERENTIATION OF STEM CELLS
US20020064855A1 (en) * 1999-08-20 2002-05-30 Ihor Lemischka Genes that regulate hematopoietic blood forming stem cells and uses thereof
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US8227578B2 (en) 2006-11-10 2012-07-24 Abe, Ikubo & Katayama Anti-human dlk-1 antibody showing anti-tumor activity in vivo
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR100982170B1 (ko) 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Also Published As

Publication number Publication date
EP2548887B1 (en) 2015-05-27
US8785392B2 (en) 2014-07-22
WO2011115323A1 (ko) 2011-09-22
CN102341408B (zh) 2014-09-10
JP5367905B2 (ja) 2013-12-11
EP2548887A1 (en) 2013-01-23
US20130202592A1 (en) 2013-08-08
BR112012023416A2 (pt) 2017-03-21
CA2792413A1 (en) 2011-09-22
CN102341408A (zh) 2012-02-01
KR100982170B1 (ko) 2010-09-15
AU2010348423A1 (en) 2012-10-25
RU2531756C2 (ru) 2014-10-27
AU2010348423B2 (en) 2014-04-10
JP2012513775A (ja) 2012-06-21
CA2792413C (en) 2015-12-01
MX342222B (es) 2016-09-21
EP2548887A4 (en) 2013-12-04
RU2012143943A (ru) 2014-04-27

Similar Documents

Publication Publication Date Title
MX2012010560A (es) Composicion para inhibir metastasis de cancer que contiene proteina de fusion dlk1-fc como ingrediente activo.
MX366155B (es) Celulas para producir iduronato-2-sulfatasa recombinante.
AU2013211824A8 (en) Fusion proteins comprising IgG2 hinge domains
CL2014002166A1 (es) Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia.
BR112015022119A2 (pt) Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
TN2014000488A1 (en) Antibody formulation
PH12015502441B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
TR201910103T4 (tr) Anti-fcrn antikorları.
CA2811364C (en) Methods and compositions for inhibiting viral entry into cells
GB2513768A (en) Complexes of cytomegalovirus proteins
PE20191815A1 (es) Formulaciones acuosas estables de adalimumab
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
JP2013231081A5 (es)
MX2016005762A (es) Region variable de anticuerpo modificada que contiene molecula de union al antigeno.
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
GB201106498D0 (en) Electrochemical pH sensor
SG10201909517WA (en) Learning and memory improver
EA201590061A1 (ru) Фармацевтическая композиция
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
IN2015DN00344A (es)
WO2012020108A3 (en) Multimeric inhibitors of viral fusion and uses thereof
WO2011115458A3 (ko) 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제
WO2012141794A3 (en) Crystal structure and peptide inhibitors of hausp deubiquitinase
MX353734B (es) Metodo para producir proteinas autologas.
MX2022007399A (es) Variantes de alfa-glucosidasa ácida diseñadas.

Legal Events

Date Code Title Description
FG Grant or registration